Nostetta Ventures

The firm does not publicly name individual investment committee members or managing partners. Its public-facing materials and portfolio disclosures attribute all activity to the firm itself, suggesting a lean team structure typical of regional first-check funds.

Sourcing relies on deep ties to universities and research centers in Finland’s North Savo region and beyond. Portfolio companies such as Marginum and Cleamix were initiated through collaborations with academic institutions, clinical partners, and national research bodies like VTT, giving Nostetta early access to commercialization-stage science.

Nostetta Ventures operates as a private-equity firm with a venture fund structure, not a single family office. Its pre-fund track record was managed through an affiliated company, Nostetta Oy, which made direct investments beginning in 2012.

The firm’s disclosed activity shows exclusively direct, equity-based investments into early-stage operating companies. There is no public record of Nostetta participating as a limited partner in external venture or private-equity funds.

Nostetta describes its strategy as early-stage, including start-up and growth phases. Portfolio entry points range from pre-revenue university spinouts, like Marginum in 2021, to expanding commercial-stage companies, like Kiho, which was scaling internationally when backed the same year.

Nostetta Oy serves as the historical investment vehicle for the team’s activities prior to the establishment of the institutional fund. Holdings such as Savroc and RPS Brewing appear on the firm’s website as part of its aggregated track record, indicating a continuous investment team and philosophy.

There is no publicly available information indicating that Nostetta operates a separate philanthropic foundation or donor-advised fund. The firm’s engagement with university and research-community partnerships is purely investment-oriented.